Faster-acting insulin aspart (NN1218)

:Type 1 and 2 diabetes
:Phase 3

Faster-acting insulin aspart is insulin aspart in a new formulation designed to accelerate the onset of action with the potential for improved meal-time glucose control.

Company announcements
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 Dec 2012)
Read more company announcements

Press releases
No press releases matching the search criteria

Scientific abstracts

No scientific abstracts matching the search criteria

You can search for more clinical trials on